Insulet Corporation $PODD Shares Sold by Brown Advisory Inc.

Brown Advisory Inc. cut its stake in Insulet Corporation (NASDAQ:PODD) by 20.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,112 shares of the medical instruments supplier’s stock after selling 7,483 shares during the quarter. Brown Advisory Inc.’s holdings in Insulet were worth $9,146,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Zions Bancorporation National Association UT purchased a new stake in shares of Insulet during the 1st quarter valued at about $26,000. SouthState Corp raised its stake in shares of Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 76 shares during the period. Kozak & Associates Inc. purchased a new stake in shares of Insulet during the second quarter valued at approximately $32,000. Golden State Wealth Management LLC lifted its position in shares of Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 69 shares in the last quarter. Finally, Trust Co. of Toledo NA OH purchased a new position in shares of Insulet in the second quarter valued at $35,000.

Insulet Price Performance

Shares of PODD opened at $304.49 on Monday. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.68. The firm has a market cap of $21.42 billion, a price-to-earnings ratio of 88.26, a PEG ratio of 2.14 and a beta of 1.37. Insulet Corporation has a 52 week low of $230.05 and a 52 week high of $354.88. The stock has a 50 day moving average of $320.31 and a 200-day moving average of $315.79.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.11. The firm had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The firm’s revenue for the quarter was up 29.9% on a year-over-year basis. During the same period last year, the business posted $1.08 earnings per share. As a group, analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Analysts Set New Price Targets

PODD has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Insulet in a report on Wednesday, October 8th. Barclays boosted their price target on Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. BTIG Research raised their price objective on Insulet from $370.00 to $380.00 and gave the company a “buy” rating in a research note on Friday, November 21st. Rothschild & Co Redburn upped their target price on Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. Finally, Zacks Research raised shares of Insulet from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and a consensus price target of $379.65.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.